Caricamento...
Therapy for Mycobacterium kansasii Infection: Beyond 2018
The current standard of care therapy for pulmonary Mycobacterium kansasii infection is isoniazid (300 mg/day), rifampin (600 mg/day), and ethambutol (15 mg/kg/day) for 12 months after achieving sputum culture negativity. Rifampin is the key drug in this regimen. The contribution of isoniazid is uncl...
Salvato in:
| Pubblicato in: | Front Microbiol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166578/ https://ncbi.nlm.nih.gov/pubmed/30319580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmicb.2018.02271 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|